Clinical Trials
70 trialsPacritinib, a Kinase Inhibitor of CSF1R, IRAK1, JAK2, and FLT3, in Adults and Pediatric Participants 12 Years of Age or Older With Myelodysplastic Syndromes or Myelodysplastic/Myeloproliferative Neoplasms
National Institutes of Health Clinical Center (CC)
Imatinib to Increase RUNX1 Activity in Participants With Germline RUNX1 Deficiency
National Institutes of Health Clinical Center (CC)
TAK-243 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndromes With Increased Blasts
National Cancer Institute (NCI)
Venetoclax in Combination With ASTX727 for the Treatment of Chronic Myelomonocytic Leukemia and Other Myelodysplastic Syndrome/Myeloproliferative Neoplasm
National Cancer Institute (NCI)
Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia
National Cancer Institute (NCI)
Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
National Cancer Institute (NCI)
Azacitidine With or Without Lenalidomide or Vorinostat in Treating Patients With Higher-Risk Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia
National Cancer Institute (NCI)
Vorinostat and Azacitidine in Treating Patients With Myelodysplastic Syndromes or Acute Myeloid Leukemia
National Cancer Institute (NCI)
BMS-986253 in Myelodysplastic Syndromes
National Institutes of Health Clinical Center (CC)
Wild-Type Reovirus in Combination With Carfilzomib and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma
National Cancer Institute (NCI)
Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission
National Cancer Institute (NCI)
Busulfan, Fludarabine Phosphate, and Anti-Thymocyte Globulin Followed By Donor Stem Cell Transplant and Azacitidine in Treating Patients With High-Risk Myelodysplastic Syndrome and Older Patients With Acute Myeloid Leukemia
National Cancer Institute (NCI)
Preventing Stem Cell Transplant Complications With a Blood Separator Machine
National Institutes of Health Clinical Center (CC)
Phase I/II Trial of Early Infusion of Rapidly-generated Multivirus Specific T Cells (MVST) to Prevent Post Transplant Viral Infections
National Institutes of Health Clinical Center (CC)
Methods in Education for Breast Cancer Genetics
National Institutes of Health Clinical Center (CC)
Tivantinib in Treating Patients With Relapsed, or Relapsed and Refractory Multiple Myeloma
National Cancer Institute (NCI)
Novel Approaches for Graft-versus-Host Disease Prevention Compared to Contemporary Controls (BMT CTN 1203)
National Heart, Lung, and Blood Institute (NHLBI)
Vorinostat, Tacrolimus, and Methotrexate in Preventing GVHD After Stem Cell Transplant in Patients With Hematological Malignancies
National Cancer Institute (NCI)
Stem Cell Transplantation for Patients With Cancers of the Blood
National Institutes of Health Clinical Center (CC)
MS-275 and GM-CSF in Treating Patients With Myelodysplastic Syndrome and/or Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphocytic Leukemia
National Cancer Institute (NCI)
Selective T-Cell Depletion to Reduce GVHD (Patients) Receiving Stem Cell Tx to Treat Leukemia, Lymphoma or MDS
National Institutes of Health Clinical Center (CC)
Cord Blood Stem Cell Transplantation Study (COBLT)
National Heart, Lung, and Blood Institute (NHLBI)
Lenalidomide and Alvocidib in Treating Patients With Relapsed or Refractory B-cell Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
National Cancer Institute (NCI)
Lenalidomide in Treating Young Patients With Relapsed or Refractory Solid Tumors or Myelodysplastic Syndromes
National Cancer Institute (NCI)
Idarubicin, Cytarabine, and Tipifarnib in Treating Patients With Newly Diagnosed Myelodysplastic Syndromes or Acute Myeloid Leukemia
National Cancer Institute (NCI)
Sibling Donor Peripheral Stem Cell Transplant or Sibling Donor Bone Marrow Transplant in Treating Patients With Hematologic Cancers or Other Diseases
National Cancer Institute (NCI)
Umbilical Cord Blood for Stem Cell Transplantation in Treating Young Patients With Malignant or Nonmalignant Diseases
National Cancer Institute (NCI)
Epoetin Alfa or Epoetin Beta With or Without Iron Infusion in Treating Anemia in Patients With Cancer
National Cancer Institute (NCI)
Intensive Compared With Nonintensive Chemotherapy in Treating Older Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome
National Cancer Institute (NCI)
Tipifarnib in Treating Patients With Myelodysplastic Syndromes
National Cancer Institute (NCI)
Combination Chemotherapy With or Without Bone Marrow Transplantation in Treating Children With Acute Myeloid Leukemia
National Cancer Institute (NCI)
Combination Chemotherapy in Treating Patients With Myelodysplastic Syndrome
National Cancer Institute (NCI)
Combination Chemotherapy in Treating Older Patients With Acute Myeloid Leukemia
National Cancer Institute (NCI)
Combination Chemotherapy With or Without Gemtuzumab Ozogamicin or Tipifarnib in Treating Patients With Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes
National Cancer Institute (NCI)
Alemtuzumab and Low-Dose Cyclosporine in Treating Patients With Severe Aplastic Anemia or Acquired Marrow Failure
National Cancer Institute (NCI)
Epoetin Alfa in Treating Chemotherapy-Related Anemia in Women With Stage I, Stage II, or Stage III Breast Cancer
National Cancer Institute (NCI)
VNP40101M in Treating Patients With Relapsed or Refractory Leukemia or Myelodysplastic Syndrome
National Cancer Institute (NCI)
3-AP and Cytarabine in Treating Patients With Hematologic Cancer
National Cancer Institute (NCI)
VNP40101M and Cytarabine in Treating Patients With Hematologic Malignancies
National Cancer Institute (NCI)
Ro 50-3821 in Treating Anemia in Patients Receiving Antineoplastic Therapy for Stage IIIB or Stage IV Non-Small Cell Lung Cancer
National Cancer Institute (NCI)
Treatment of Bone Marrow to Prevent Graft-Versus-Host Disease in Patients With Acute or Chronic Leukemia Undergoing Bone Marrow Transplantation
National Cancer Institute (NCI)
Decitabine in Treating Patients With Myelodysplastic Syndrome
National Cancer Institute (NCI)
Combination Chemotherapy Followed By Peripheral Stem Cell Transplantation or Isotretinoin in Treating Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Acute Lymphocytic Leukemia
National Cancer Institute (NCI)
Thalidomide and Epoetin Alfa in Treating Anemia in Patients With Myelodysplastic Syndrome
National Cancer Institute (NCI)
Epoetin Beta in Treating Anemia in Patients With Cervical Cancer
National Cancer Institute (NCI)
Bevacizumab in Treating Patients With Myelodysplastic Syndrome
National Cancer Institute (NCI)
Flavopiridol and Vorinostat in Treating Patients With Relapsed or Refractory Acute Leukemia or Chronic Myelogenous Leukemia or Refractory Anemia
National Cancer Institute (NCI)
Donor Stem Cell Transplant After Conditioning Therapy in Treating Patients With Hematologic Cancer, Recurrent or Metastatic Solid Tumor, or Other Disease
National Cancer Institute (NCI)
Donor Stem Cell Transplant After Busulfan, Fludarabine, and Antithymocyte Globulin in Treating Patients With Hematological Cancer
National Cancer Institute (NCI)
Tipifarnib in Treating Patients With Advanced Hematologic Cancer
National Cancer Institute (NCI)